Camlin Fine Sciences 과거 순이익 실적
과거 기준 점검 0/6
Camlin Fine Sciences 의 수입은 연평균 -34.1%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 6.1%의 비율로 증가했습니다. 매출은 연평균 6.2%의 비율로 증가해 왔습니다.
핵심 정보
-34.11%
순이익 성장률
-37.73%
주당순이익(EPS) 성장률
| Chemicals 산업 성장률 | 17.68% |
| 매출 성장률 | 6.16% |
| 자기자본이익률 | -3.15% |
| 순이익률 | -1.59% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.내러티브 업데이트 • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).내러티브 업데이트 • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).내러티브 업데이트 • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).내러티브 업데이트 • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).내러티브 업데이트 • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.내러티브 업데이트 • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.내러티브 업데이트 • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).내러티브 업데이트 • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.내러티브 업데이트 • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.새로운 내러티브 • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Camlin Fine Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 17,233 | -274 | 2,439 | 0 |
| 31 Dec 25 | 17,780 | -141 | 2,544 | 0 |
| 30 Sep 25 | 17,517 | 187 | 2,386 | 0 |
| 30 Jun 25 | 17,092 | 825 | 2,262 | 0 |
| 31 Mar 25 | 16,665 | 685 | 2,129 | 0 |
| 31 Dec 24 | 16,540 | -2,155 | 2,470 | 0 |
| 30 Sep 24 | 16,064 | -2,231 | 2,406 | 0 |
| 30 Jun 24 | 15,893 | -1,423 | 2,315 | 0 |
| 31 Mar 24 | 14,539 | 651 | 1,977 | 0 |
| 31 Dec 23 | 16,381 | -8 | 1,931 | 0 |
| 30 Sep 23 | 16,400 | 350 | 1,893 | 0 |
| 30 Jun 23 | 17,174 | 674 | 1,850 | 0 |
| 31 Mar 23 | 16,816 | 577 | 1,823 | 0 |
| 31 Dec 22 | 16,441 | 581 | 1,727 | 0 |
| 30 Sep 22 | 16,371 | 628 | 1,710 | 0 |
| 30 Jun 22 | 14,650 | 442 | 1,666 | 0 |
| 31 Mar 22 | 14,121 | 650 | 1,582 | 0 |
| 31 Dec 21 | 13,495 | 598 | 1,521 | 0 |
| 30 Sep 21 | 12,666 | 465 | 1,436 | 0 |
| 30 Jun 21 | 12,122 | 579 | 1,375 | 0 |
| 31 Mar 21 | 11,871 | 510 | 1,301 | 0 |
| 31 Dec 20 | 11,533 | 394 | 1,312 | 0 |
| 30 Sep 20 | 11,293 | 291 | 1,255 | 0 |
| 30 Jun 20 | 10,948 | 302 | 1,207 | 0 |
| 31 Mar 20 | 10,491 | 303 | 1,180 | 0 |
| 31 Dec 19 | 10,243 | 349 | 1,170 | 0 |
| 30 Sep 19 | 9,918 | 277 | 1,139 | 0 |
| 30 Jun 19 | 9,709 | 221 | 1,121 | 0 |
| 31 Mar 19 | 8,922 | 6 | 1,092 | 0 |
| 31 Dec 18 | 8,523 | -139 | 1,053 | 0 |
| 30 Sep 18 | 8,186 | -222 | 1,016 | 0 |
| 30 Jun 18 | 7,634 | -277 | 969 | 0 |
| 31 Mar 18 | 7,206 | -338 | 935 | 0 |
| 31 Dec 17 | 6,403 | -367 | 865 | 20 |
| 30 Sep 17 | 5,676 | -311 | 843 | 20 |
| 30 Jun 17 | 5,347 | -275 | 820 | 22 |
| 31 Mar 17 | 5,339 | -128 | 820 | 0 |
| 31 Dec 16 | 5,149 | 98 | 737 | 21 |
| 30 Sep 16 | 5,013 | 174 | 649 | 21 |
| 30 Jun 16 | 5,063 | 232 | 496 | 21 |
| 31 Mar 16 | 4,893 | 358 | 562 | 21 |
| 31 Dec 15 | 5,083 | 445 | 879 | 25 |
| 30 Sep 15 | 5,238 | 463 | 906 | 25 |
| 30 Jun 15 | 5,531 | 552 | 883 | 25 |
양질의 수익: 532834 은(는) 현재 수익성이 없습니다.
이익 마진 증가: 532834는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: 532834은 수익성이 없으며 지난 5년 동안 손실이 연평균 34.1% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 532834의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: 532834은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(12.6%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: 532834는 현재 수익성이 없으므로 자본 수익률이 음수(-3.15%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/10 21:44 |
| 종가 | 2026/06/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Camlin Fine Sciences Limited는 9명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |